Citations

Clear

184 citation(s) found for "Brenner, J".

Real-World Treatment Strategies to Improve Outcomes in Patients With Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation
Harris, Lucinda A. , Chang, Christopher H., Poppers, David M., Kassebaum-Ladewski, Amy, Sayuk, Gregory S. , Brenner, Darren M. , Waldman, Scott A.

Mayo Clinic

American Journal of Gastroenterology | March 31, 2022 | Volume: 117 | Issue: 4S | Pages: S21-S26

10.14309/ajg.0000000000001709 | PMID 35354772 Get It

Chronic idiopathic constipation and irritable bowel syndrome with constipation are complex, overlapping conditions. Although multiple guidelines have informed healthcare providers on appropriate treatment options for patients with chronic idiopathic constipation and irritable bowel syndrome with constipation, little direction is offered on treatment selection. First-line treatment options usually include fiber and over-the-counter osmotic laxatives; however, these are insufficient for many individuals. When these options fail, prescription secretagogues (plecanatide, linaclotide, lubiprostone, and tenapanor [pending commercial availability]), or serotonergic agents (prucalopride and tegaserod) are generally preferred. Individuals experiencing concurrent abdominal pain and/or bloating may experience greater overall improvements from prescription therapies because these agents have been proven to reduce concurrent abdominal and bowel symptoms. Should initial prescription treatments fail, retrying past treatment options (if not adequately trialed initially), combining agents from alternative classes, or use of adjunctive therapies may be considered. Given the broad spectrum of available agents, therapy should be tailored by mutual decision-making between the patient and practitioner. Overall, patients need to be actively monitored and managed to maximize clinical outcomes.
A Genome-Wide Gene-Based Gene–Environment Interaction Study of Breast Cancer in More than 90,000 Women
Chen, Hongjie , Middha, Pooja , Bolla, Manjeet K. , Wang, Qin , Michailidou, Kyriaki , Hopper, John L. , Shibli, Rana , Aronson, Kristan J. , Hodge, James M. , Brenner, Hermann , Hoppe, Reiner , Lo, Wing‐Yee, Mannermaa, Arto , Kosma, Veli‐Matti , Jung, Audrey , Haiman, Christopher A. , Simard, Jacques , Goldberg, Mark S. , García‐Closas, Montserrat , Yang, Rose, Evans, D. Gareth , Howell, Anthony , Orr, Nick , Wang, Sophia , Easton, Douglas F. , Chang‐Claude, Jenny , Lindström, Sara , Winham, Stacey, Evans, D Gareth , Brenner, Hermann , Kapoor, Pooja Middha , García-Closas, Montserrat , Michailidou, Kyriaki , Hodge, James M , Simard, Jacques , Wang, Sophia S , Jung, Audrey Y , Orr, Nick , Wang, Xiaoliang , Su, Yu-Ru , Dennis, Joe , Dunning, Alison M. , Lush, Michael J. , Pharoah, Paul D.P. , Southey, Melissa C. , Koutros, Stella , Freeman, Laura E. Beane , Stone, Jennifer , Rennert, Gad , Murphy, Rachel A. , Guénel, Pascal , Truong, Thérèse , Teras, Lauren R. , Canzian, Federico , Kaaks, Rudolf , Arndt, Volker , Behrens, Sabine , Becher, Heiko , Giles, Graham G. , Maskarinec, Gertraud , Scott, Christopher G. , Winham, Stacey J. , Zheng, Wei , Long, Jirong , Troester, Melissa A. , Love, Michael I. , Peng, Cheng , Tamimi, Rulla M. , Eliassen, A. Heather , Figueroa, Jonine D. , Ahearn, Thomas U. , Hall, Per N , Czene, Kamila , Wolk, Alicja , Sandler, Dale P. , Taylor, Jack A. , Swerdlow, Anthony J. , Lacey, James V. , Olsson, Håkan , Milne, Roger L. , Hsu, Li , Kraft, Peter

Mayo Clinic

Cancer Research Communications | March 25, 2022 | Volume: 2 | Issue: 4 | Pages: 211-219

10.1158/2767-9764.crc-21-0119 | PMID 36303815 Get It

Genome-wide association studies (GWAS) have identified more than 200 susceptibility loci for breast cancer, but these variants explain less than a fifth of the disease risk. Although gene–environment interactions have been proposed to account for some of the remaining heritability, few studies have empirically assessed this. We obtained genotype and risk factor data from 46,060 cases and 47,929 controls of European ancestry from population-based studies within the Breast Cancer Association Consortium (BCAC). We built gene expression prediction models for 4,864 genes with a significant (P < 0.01) heritable component using the transcriptome and genotype data from the Genotype-Tissue Expression (GTEx) project. We leveraged predicted gene expression information to investigate the interactions between gene-centric genetic variation and 14 established risk factors in association with breast cancer risk, using a mixed-effects score test. After adjusting for number of tests using Bonferroni correction, no interaction remained statistically significant. The strongest interaction observed was between the predicted expression of the C13orf45 gene and age at first full-term pregnancy (PGXE = 4.44 × 10−6). In this transcriptome-informed genome-wide gene–environment interaction study of breast cancer, we found no strong support for the role of gene expression in modifying the associations between established risk factors and breast cancer risk. Our study suggests a limited role of gene–environment interactions in breast cancer risk.
Abstract 11: The Utility of Causative Classification System: Correlation between Causative and Phenotypic Stroke Subtypes
Barrett, Kevin M. , Biffi, Alessandro , Gamble, Dale M., Grazer, Anja, Gschwendtner, Andreas, Helenius, Johanna, Huq, Mohammed Saiful, Katschnig, Petra , Katsnelson, Michael , Kittner, Steven J. , Malik, Shaneela , Ossi, Raid G., Peddareddygari, Leema Reddy , Pucek, Mateusz, Saraf, Neha, Sheikh, Huma U., Stoegerer, Eva, Weissman, Darren, Woo, Daniel , Worrall, Bradford B. , Ay, Hakan , Arsava, Ethem Murat , Brenner, David A. , Brown, Robert , Huq, Mohammed, Li, Linxin , Labovitz, Daniel , Meschia, James F. , Rannikmäe, Kristiina , Rhodes, David , Southerland, Andrew M.

Mayo Clinic

Stroke | March 20, 2022 | Volume: 43 | Issue: suppl_1 | Pages: No page available

10.1161/str.43.suppl_1.a11 Get It

Background: Causative Classification of Stroke (CCS) system is a novel, web-based, and fully-computerized algorithm that integrates clinical, diagnostic, and etiologic stroke characteristics in an evidence-based manner (available at http://ccs.mgh.harvard.edu ) and provides in a given patient both phenotypic subtypes where abnormal evaluation findings are simply organized in major etiologic categories and causative subtypes where abnormal evaluation findings are filtered through a decision making process to identify the most likely cause of stroke. In this study, we sought to identify the concordance between phenotypic and causative CCS subtypes in the NINDS Stroke Genetics Network (SiGN). Methods: A total of 24 adjudicators from 15 US and European sites certified in CCS retrospectively determined CCS subtypes through chart review in 7134 patients. The CCS software provided causative subtypes in 3 confidence levels as “evident”, “probable” or “possible” based on the weight of causal evidence. We estimated how often CCS classified a given major abnormal evaluation finding as the causative stroke mechanism. Results: CCS assigned 55% of patients with the phenotype of moderate-to-severe atherosclerotic stenosis into the causative category of “evident large artery atherosclerosis”. Likewise, 50% of patients with a major cardiac source (such as atrial fibrillation) were classified into “evident cardio-aortic embolism”, and 74% of those with imaging evidence of a typical lacunar infarct into “evident small artery occlusion”. In 20% to 30% of patients, phenotypic and causative categories were the same but the causative subtype was assigned with a lower level of confidence. Six to 20% of patients with a given phenotypic feature were classified into a different causative category. Failure to investigate for other subtypes in the presence of a positive test finding and the presence of multiple competing etiologies were key contributors to the observed disconcordance between phenotypic and causative subtypes. Conclusions: Our findings show that the presence of a major abnormality in stroke evaluation does not necessarily mean that it is always the cause. The ability of CCS system to discriminate between phenotypic and causative characteristics of stroke etiology provides the opportunity to refine stroke phenotypes for use in research studies.
Abstract P2-13-45: Interim results of a phase 1 study of the novel immunotoxin MT-5111 in patients with HER2+tumors
Tine, Brian Andrew Van, Mita, Monica , Valdes, Frances, Ahn, Daniel H. , Starr, Jason S. , Georgy, Angela, Pelham, Joshua, Anand, Banmeet S. , Strack, Thomas , Sandri, Andrés Machado, Barve, Minal , Hamilton, Erika , Brenner, Andrew Jacob , Hubbard, Joleen M. , Wainberg, Zev A.

Mayo Clinic

Cancer Research | March 8, 2022 | Volume: 82 | Issue: 4_Supplement | Pages: P2-13-45-P2-13-45

10.1158/1538-7445.sabcs21-p2-13-45 Get It

Abstract Background: Engineered toxin bodies (ETBs) are composed of a de-immunized Shiga-like Toxin A subunit genetically fused to an antibody-like binding domain. ETBs can force receptor internalization, induce potent cell-kill via enzymatic and permanent inactivation of ribosomes, and may not be subject to resistance mechanisms of other therapeutics. MT-5111 is a 55 kD ETB targeting HER2 in solid tumors that binds to an epitope distinct from trastuzumab and pertuzumab, offering potential combination strategies with other HER2-targeting agents. MT-5111 may demonstrate efficacy in patients (pts) resistant to other HER2-targeting agents, as its mechanism of action does not rely on inhibition of kinase signaling or cytoskeletal or DNA damage. Methods: The primary objective is to determine the maximum tolerated dose (MTD) of MT-5111 monotherapy in adult pts with advanced HER2+ solid tumors. Secondary objectives are pharmacokinetics (PK), efficacy, and immunogenicity. Using a modified 3+3 design, the dose-escalation part of the study enrolls pts with HER2+ tumors into 7 cohorts: 0.5, 1, 2, 3, 4.5, 6.75, and 10 µg/kg/dose. Three dose-expansion cohorts will follow for HER2+ breast cancer, gastro-esophageal cancer, and other HER2+ tumors. All pts receive MT-5111 weekly as 30-min IV infusions in each 21-day treatment (tx) cycle (C) until disease progression (PD), unacceptable toxicity, death, or withdrawn consent (NCT04029922). Results: Per data cut in June 2021, 21 pts (mean age 64 years, range 34-78; 38% male) in cohorts 1-6 with breast (n=7), biliary (n=6), gastric (n=3), pancreatic (n=2), lung (n=2), and colon (n=1) cancer were treated (Table 1). Pts had a median of 4 prior lines of systemic therapies (range, 1-8) and 2 prior lines of HER2-targeting treatments (range, 0-6). No Grade (G)4 or 5 tx-emergent (TE) adverse events (AEs) occurred. Tx-related AEs occurred in 11 (52%) pts; the most common was fatigue (n=7, 33%). One pt (4.5 µg/kg) had a possibly (per PI) related G3 serious AE (SAE) of dyspnea and hypoxia, but also lymphangitic carcinomatosis and H. influenzae infection. The other related SAE occurred in a pt (6.75 µg/kg) who had a G1 transient troponin increase without concomitant cardiac symptoms or ECG/ECHO changes. All other related AEs were ≤G2. There were no clinically significant changes in cardiac biomarkers (troponin, ECG, left ventricular ejection fraction) nor were there cases of capillary leak syndrome. Two pts (3 µg/kg and 4.5 µg/kg) had reversible G2 infusion-related reactions. Best response to date has been stable disease. AUClast data matched PK simulations based on non-human primate studies, and Cmax data at 6.75 µg/kg indicated that current in-human exposure was between the IC50 values of high and medium HER2-expressing cell lines (approximately 10-89 ng/mL). Thus, a dose of at least 10 µg/kg may be required to achieve effective exposure. To date, no dose-limiting toxicities have been observed and the 10 µg/kg/dose cohort is now accruing. Conclusions: MT-5111 was well tolerated with no clinically significant immuno- or cardiotoxicity. Dose escalation is ongoing and nearing levels expected to be required for efficacious exposure. Table 1.Metastatic HER2 status and MT-5111 treatment by cohortDose0.5 µg/kg1.0 µg/kg2.0 µg/kg3.0 µg/kg4.5 µg/kg6.75 µg/kgCohort123456Number of patients treated with MT-5111433335Metastatic HER2 2+ by IHC: ALL/BC1/11/11/01/10/04/0Metastatic HER2 3+ by IHC: ALL/BC3/12/02/12/13/01/1BC, breast cancer. Citation Format: Brian A. Van Tine, Monica Mita, Minal A. Barve, Erika P. Hamilton, Andrew J. Brenner, Frances Valdes, Daniel Ahn, Joleen Hubbard, Jason Starr, Angela Georgy, Joshua Pelham, Banmeet S. Anand, Thomas Strack, Andrés Machado Sandri, Zev A. Wainberg. Interim results of a phase 1 study of the novel immunotoxin MT-5111 in patients with HER2+tumors [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P2-13-45.
A phase 1 study of the novel immunotoxin MT-5111 in patients with HER2+tumors: Interim results.
Tine, Brian Andrew Van, Mita, Monica , Valdes, Frances, Ahn, Daniel H. , Starr, Jason S. , Pelham, Joshua, Anand, Banmeet S. , Strack, Thomas , Sandri, Andrés Machado, Hubbard, Joleen M. , Barve, Minal , Hamilton, Erika , Brenner, Andrew Jacob , Lerner, Susan A. , Wainberg, Zev A.

Mayo Clinic

Journal of Clinical Oncology | January 19, 2022 | Volume: 40 | Issue: 4_suppl | Pages: 297-297

10.1200/jco.2022.40.4_suppl.297 Get It

297 Background: MT-5111 is a 55 kD engineered toxin body (ETB) targeting HER2 in solid tumors that binds to an epitope distinct from trastuzumab and pertuzumab, offering potential combination strategies with other HER2-targeting agents. MT-5111 may demonstrate efficacy in patients (pts) resistant to other HER2-targeting agents, as its mechanism of action induces direct cell kill via enzymatic and permanent ribosome destruction and does not rely on inhibition of kinase signaling or cytoskeletal or DNA damage. Methods: This is a phase 1 study in adult pts with advanced HER2+ solid tumors. The dose-escalation portion (modified 3+3 design) enrolls pts into sequential cohorts followed by expansion cohorts for HER2+ breast cancer (BC), gastric or gastroesophageal junction adenocarcinoma (GEA), and other HER2+ tumors. MT-5111 is dosed weekly IV over 30 min in each 21-day treatment (tx) cycle until disease progression, unacceptable toxicity, death, or withdrawn consent. Results: As of Sep 2021 (contains preliminary data), 24 pts (mean age 64 yrs) were treated, 13 (54%) of whom had gastrointestinal (GI) tumors (6 biliary, 3 GEA, 2 pancreatic, 2 colo/rectal) (Table). Pts with GI tumors had a median of 3 prior systemic tx and 1 prior HER2-targeting tx. No Grade (G) 4/5 tx-emergent adverse events (AEs) occurred. Tx-related AEs occurred in 13 (54%) pts, most commonly fatigue (n=7, 29%). One pt with biliary cancer and concurrent lymphangitic carcinomatosis and H. influenzae infection (4.5 µg/kg) had a possibly related G3 serious AE (SAE) of dyspnea, which resolved 9 days later. Another related SAE occurred in a pt with GEA (6.75 µg/kg) who had a G1 transient troponin increase that resolved during hospitalization, with no clinical symptoms or ECG/ECHO changes; the pt withdrew from study before further dosing. All other related AEs were ≤G2. No other clinically significant changes in cardiac biomarkers (troponin, ECG, LVEF) or cases of capillary leak syndrome occurred. Two pts (3 and 4.5 µg/kg) had reversible G2 infusion-related reactions. Best response to date has been stable disease. AUClast data matched PK simulations based on non-human primate studies. Cmax data at 10 µg/kg indicate that current in-pt exposure was between IC50 values of high and medium HER2-expressing cell lines (approx 10-89 ng/mL). Thus, at least 10 µg/kg may be required to achieve effective exposure. No dose-limiting toxicities have been observed. The 10 µg/kg cohort is now accruing. Following this cohort, an expansion cohort for pts with BC will open. Conclusions: MT-5111 was well tolerated with no clinically significant immuno/cardiotoxicity. Dose escalation is ongoing and is nearing levels expected to be required for efficacious exposure. Clinical trial information: NCT04029922. [Table: see text]
Accounting for EGFR Mutations in Epidemiologic Analyses of Non–Small Cell Lung Cancers: Examples Based on the International Lung Cancer Consortium Data
Schmid, Sabine , Jiang, Mei , Brown, M. Catherine , Fares, Aline Fusco , García-Pardo, Miguel , Soriano, Joelle , Dong, Mei , Thomas, Sera , Kohno, Takashi , Leal, Letícia Ferro , Diao, Nancy , Xie, Juntao , Wang, Zhichao , Заридзе, Давид , Świątkowska, Beata , Savić, Milan , Wenzlaff, Angela S. , Harris, Curtis C. , Caporaso, Neil E. , Ma, Hongxia , Fernández‐Tardón, Guillermo , Barnett, Matthew J, Goodman, Gary E. , Davies, Michael P.A. , Pérez‐Ríos, Mónica , Taylor, Fiona, Schoettker, Ben, Brenner, Hermann , Andrew, Angeline S. , Cox, Angela , Field, John K. , Wang, Ying , Chen, Chu , Tardón, Adonina , Shete, Sanjay , Shen, Hongbing , Landi, Maria Teresa , Schwartz, Ann G. , Qi, Lihong , Brennan, Paul , Reis, Rui Manuel , Liu, Geoffrey , Świątkowska, Beata , Mates, Dana , Wenzlaff, Angela S , Fernandez-Tardon, Guillermo , Barnett, Matthew J , Davies, Michael P A , Duell, Eric J , Brenner, Hermann , Cox, Angela , Ruano-Ravina, Alberto , Field, John K , Tardón, Adonina , Schabath, Matthew B , Schwartz, Ann G , Sakoda, Lori C , Brennan, Paul , Yang, Ping , Christiani, David C. , Reis, Rui Manuel , Hung, Rayjean J , Liu, Geoffrey , Shen, Hongbing , Dong, Mei , Holcátová, Ivana , Lissowska, Jolanta , Mateș, Dana , Duell, Eric J. , Marchand, Loı̈c Le , Schabath, Matthew B. , Ryan, Bríd M. , Sakoda, Lori C. , Yang, Ping , Zhang, Jie , Shiraishi, Kouya , Hung, Rayjean J. , Xu, Wei

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | January 13, 2022 | Volume: 31 | Issue: 3 | Pages: 679-687

10.1158/1055-9965.epi-21-0747 | PMID 35027437 Get It

Abstract Background: Somatic EGFR mutations define a subset of non–small cell lung cancers (NSCLC) that have clinical impact on NSCLC risk and outcome. However, EGFR-mutation-status is often missing in epidemiologic datasets. We developed and tested pragmatic approaches to account for EGFR-mutation-status based on variables commonly included in epidemiologic datasets and evaluated the clinical utility of these approaches. Methods: Through analysis of the International Lung Cancer Consortium (ILCCO) epidemiologic datasets, we developed a regression model for EGFR-status; we then applied a clinical-restriction approach using the optimal cut-point, and a second epidemiologic, multiple imputation approach to ILCCO survival analyses that did and did not account for EGFR-status. Results: Of 35,356 ILCCO patients with NSCLC, EGFR-mutation-status was available in 4,231 patients. A model regressing known EGFR-mutation-status on clinical and demographic variables achieved a concordance index of 0.75 (95% CI, 0.74–0.77) in the training and 0.77 (95% CI, 0.74–0.79) in the testing dataset. At an optimal cut-point of probability-score = 0.335, sensitivity = 69% and specificity = 72.5% for determining EGFR-wildtype status. In both restriction-based and imputation-based regression analyses of the individual roles of BMI on overall survival of patients with NSCLC, similar results were observed between overall and EGFR-mutation-negative cohort analyses of patients of all ancestries. However, our approach identified some differences: EGFR-mutated Asian patients did not incur a survival benefit from being obese, as observed in EGFR-wildtype Asian patients. Conclusions: We introduce a pragmatic method to evaluate the potential impact of EGFR-status on epidemiological analyses of NSCLC. Impact: The proposed method is generalizable in the common occurrence in which EGFR-status data are missing.
Risk Stratification for Early-Onset Colorectal Cancer Using a Combination of Genetic and Environmental Risk Scores: An International Multi-Center Study
Archambault, Alexi , Jeon, Jihyoun , Thomas, Minta , Harrison, Tabitha A. , Bishop, D. Timothy , Brenner, Hermann , Casey, Graham , Chan, Andrew T. , Chang‐Claude, Jenny , Figueiredo, Jane C. , Gallinger, Steven , Gruber, Stephen B. , Gunter, Marc J. , Hoffmeister, Michael , Li, Li , Pai, Rish K. , Parfrey, Patrick S. , Rennert, Gad , Lee, Jeffrey K. , Slattery, Martha L. , Win, Aung Ko , Woods, Michael O. , Peterse, Elisabeth F.P. , Cao, Yin , Du, Mengmeng , Corley, Douglas A. , Peters, Ulrike , Song, Mingyang , Archambault, Alexi N , Harrison, Tabitha A , Bishop, D Timothy , Brenner, Hermann , Chan, Andrew T , Chang-Claude, Jenny , Figueiredo, Jane C , Gruber, Stephen B , Gunter, Marc J , Guo, Feng , Hoffmeister, Michael , Jenkins, Mark A , Marchand, Loïc Le , Moreno, Victor , Pai, R K , Rennert, Gad , Sakoda, Lori C , Song, Mingyang , Win, Aung K , Woods, Michael O , Murphy, Neil , Campbell, Peter T , Peterse, Elisabeth F P , Cao, Yin , Liang, Peter S , Hayes, Richard B , Jeon, Jihyoun , Lin, Yi , Jenkins, Mark A. , Keku, Temitope O , Marchand, Loı̈c Le , Moreno, Vı́ctor , Newcomb, Polly A. , Sakoda, Lori C. , Song, Mingyang , Murphy, Neil , Campbell, Peter T. , Su, Yu-Ru , Lansdorp‐Vogelaar, Iris , Zeleniuch‐Jacquotte, Anne , Liang, Peter S. , Hsu, Li , Hayes, Richard B.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | January 11, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/jnci/djac003 | PMID 35026030 Get It

AbstractBackgroundThe incidence of colorectal cancer (CRC) among individuals aged younger than 50 years has been increasing. As screening guidelines lower the recommended age of screening initiation, concerns including the burden on screening capacity and costs have been recognized, suggesting that an individualized approach may be warranted. We developed risk prediction models for early-onset CRC that incorporate an environmental risk score (ERS), including 16 lifestyle and environmental factors, and a polygenic risk score (PRS) of 141 variants.MethodsRelying on risk score weights for ERS and PRS derived from studies of CRC at all ages, we evaluated risks for early-onset CRC in 3486 cases and 3890 controls aged younger than 50 years. Relative and absolute risks for early-onset CRC were assessed according to values of the ERS and PRS. The discriminatory performance of these scores was estimated using the covariate-adjusted area under the receiver operating characteristic curve.ResultsIncreasing values of ERS and PRS were associated with increasing relative risks for early-onset CRC (odds ratio per SD of ERS = 1.14, 95% confidence interval [CI] = 1.08 to 1.20; odds ratio per SD of PRS = 1.59, 95% CI = 1.51 to 1.68), both contributing to case-control discrimination (area under the curve = 0.631, 95% CI = 0.615 to 0.647). Based on absolute risks, we can expect 26 excess cases per 10 000 men and 21 per 10 000 women among those scoring at the 90th percentile for both risk scores.ConclusionsPersonal risk scores have the potential to identify individuals at differential relative and absolute risk for early-onset CRC. Improved discrimination may aid in targeted CRC screening of younger, high-risk individuals, potentially improving outcomes.
Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019
Kocarnik, Jonathan , Compton, Kelly, Dean, Frances , Fu, Weijia , Gaw, Brian, Harvey, James , Henrikson, Hannah , Lu, Dan , Pennini, Alyssa, Xu, Rixing, Ababneh, Emad , Abbasi‐Kangevari, Mohsen , Abbastabar, Hedayat , Abd‐Elsalam, Sherief , Abedi, Aidin , Abidi, Hassan , Abolhassani, Hassan , Adedeji, Isaac Akinkunmi , Advani, Shailesh M, Aghaali, Mohammad , Ahmad, Tauseef , Rashid, Tarik A. , Salih, Yusra Ahmed , Aklilu, Addis , Akram, Tayyaba , Akunna, Chisom Joyqueenet , Hamad, Hanadi Al , Alahdab, Fares , Alimohamadi, Yousef, Alipour, Vahid, Alkhayyat, Motasem , Almasri, Nihad A. , Al‐Maweri, Sadeq Ali , Almustanyir, Sami , Alonso, Nivaldo , Alvis‐Guzmán, Nelson , Amu, Hubert , Ansari, Fereshteh, Antwi, Maxwell Hubert , Anvari, Davood , Anyasodor, Anayochukwu Edward , Aqeel, Muhammad , Arabloo, Jalal , Aremu, Olatunde , Ariffin, Hany , Aripov, Timur , Arshad, Muhammad , Artaman, Al, Arulappan, Judie , Jafarabadi, Mohammad Asghari , Ashraf, Tahira , Atorkey, Prince , Ausloos, Marcel , Awedew, Atalel Fentahun , Quintanilla, Beatriz Paulina Ayala , Ayenew, Temesgen , Azab, Mohammed A. , Azadnajafabad, Sina , Jafari, Amirhossein Azari , Azarian, Ghasem , Badiye, Ashish , Bahadory, Saeed , Baig, Atif Amin , Baker, Jennifer L. , Balakrishnan, Senthilkumar , Bärnighausen, Till , Barone‐Adesi, Francesco , Barrow, Amadou , Belgaumi, Uzma , Bezabhe, Woldesellassie, Bezabih, Yihienew Mequanint , Bhagat, Devidas S. , Bhagavathula, Akshaya Srikanth , Bhardwaj, Nikha , Bhaskar, Sonu , Bhojaraja, Vijayalakshmi S, Bibi, Sadia , Bijani, Ali , Bisignano, Catherine, Bolarinwa, Obasanjo Afolabi , Bolla, Srinivasa Rao , Braithwaite, Dejana , Brar, Amanpreet , Brenner, Hermann , Bustamante-Teixeira, Maria Teresa , Butt, Nadeem Shafique , Butt, Zahid A , Santos, Florentino Luciano Caetano dos , Cao, Yin , Carreras, Giulia , Catalá-López, Ferrán , Cembranel, Francieli , Cerin, Ester , Cernigliaro, Achille , Chakinala, Raja Chandra , Chattu, Soosanna Kumary , Chattu, Vijay Kumar , Chaturvedi, Pankaj, Chimed‐Ochir, Odgerel , Cho, Daniel , Chu, Dinh‐Toi , Conde, João , Cortés, Sandra , Cortesi, Paolo Angelo, Costa, Vera Marisa , Cunha, Amanda Ramos da , Dadras, Omid , Dagnew, Amare Belachew , Dandona, Lalit , Dandona, Rakhi , Hoz, Fernando de la , Dhamnetiya, Deepak , Dhimal, Mandira Lamichhane , Díaz, Daniel , Djalalinia, Shirin , Doaei, Saeid , Dorostkar, Fariba, Driscoll, Tim , Ebrahimi, Hedyeh , Eftekharzadeh, Sahar , Tantawi, Maha El , El‐Abid, Hassan , Elbarazi, Iffat , Elhabashy, Hala Rashad , Elhadi, Muhammed , Eshrati, Babak, Esmaeilzadeh, Firooz , Etemadi, Arash , Ezzikouri, Sayeh , Faisaluddin, Mohammed, Fares, Jawad , Farzadfar, Farshad , Feroze, Abdullah , Desideri, Lorenzo Ferro , Fischer, Florian , Fisher, James L. , Fukumoto, Takeshi , Gad, Mohamed M. , Fonseca, Mariana Gaspar, Obsa, Abera Getachew, Ghafourifard, Mansour , Ghashghaee, Ahmad , Ghith, Nermin , Gholamalizadeh, Maryam , Gilani, Syed Amir , Gizaw, Abraham Tamirat , Glasbey, James , Golechha, Mahaveer , Goleij, Pouya , Gopalani, Sameer Vali , Gorini, Giuseppe , Goudarzi, Houman , Gubari, Mohammed Ibrahim Mohialdeen , Guerra, Maximiliano Ribeiro, Guha, Avirup , Gunasekera, Sanjeeva , Gupta, Bhawna , Gupta, Vivek , Gutiérrez, Reyna Alma, Hafezi‐Nejad, Nima , Haider, Mohammad Rifat , Hameed, Sajid , Hanif, Asif , Haque, Shafiul , Harlianto, Netanja I. , Hasaballah, Ahmed I , Hay, Simon I , Heidari, Golnaz , Herrera-Serna, Brenda Yuliana , Herţeliu, Claudiu , Hezam, Kamal , Hossain, Mohammad Bellal , Hosseini, Mohammad‐Salar , Hosseini, Mostafa, Hosseinzadeh, Mehdi , Hostiuc, Mihaela , Househ, Mowafa , Hsaïri, Mohamed, Huang, Junjie , Hugo, Fernando Neves , Hussain, Rabia , Hussein, Nawfal R , Hwang, Bing‐Fang , Ibitoye, Segun Emmanuel , Ida, Fidelia , Ikuta, Kevin S , Ilić, Irena , Irham, Lalu Muhammad , Islam, Jessica Y. , Islam, Sheikh Mohammed Shariful , Ismail, Nahlah Elkudssiah , Isola, Gaetano , Iwagami, Masao , Jacob, Louis , Jain, Vardhmaan , Jakovljević, Mihajlo, Javaheri, Tahereh , Jayaram, Shubha, Jha, Ravi Prakash , Jonas, Jost B, Joó, Tamás , Joseph, Nitin , Joukar, Farahnaz, Jürisson, Mikk , Kalankesh, Leila R , Kalhor, Rohollah , Kalkonde, Yogeshwar , Kamath, Ashwin , Al-Salihi, Nawzad Kameran, Kandel, Himal , Kapoor, Neeti , Kasa, Ayele Semachew , Keshavarz, Pedram , Keykhaei, Mohammad , Khader, Yousef , Khalilov, Rovshan , Khan, Maseer , Khan, Md Nuruzzaman , Khan, Moien AB , Khang, Young-Ho, Khater, Amir M, Kısa, Adnan , Kısa, Sezer , Kopec, Jacek A , Koteeswaran, Rajasekaran , Koul, Parvaiz A , Laxminarayana, Sindhura Lakshmi Koulmane , Biçer, Burcu Küçük , Kugbey, Nuworza , Kumar, G Anil , Kurmi, Om , Kutluk, Tezer, Lami, Faris Hasan, Lee, Yo Han , Leigh, James , Leong, Elvynna , Li, Ming‐Chieh , Liu, Xuefeng , Loureiro, Joana A. , Lunevičius, Raimundas , Razek, Muhammed Magdy Abd El, Majeed, Azeem , Makki, Alaa, Male, Shilpa, Malik, Ahmad Azam , Martini, Santi , Masoumi, Seyedeh Zahra , Mehrotra, Ravi , Mendoza, Walter, Mengesha, Endalkachew Worku , Mesregah, Mohamed Kamal , Jonasson, Junmei Miao , Miazgowski, Bartosz , Miazgowski, Tomasz , Michałek, Irmina Maria , Miller, Ted R. , Mirzaei, Hamid Reza , Misra, Sanjeev , Mithra, Prasanna , Moghadaszadeh, Masoud, Mohammad, Karzan Abdulmuhsin , Mohammad, Yousef , Mohammadi, Mokhtar , Mohammadi, Seyyede Momeneh, Mohammadian-Hafshejani, Abdollah , Mohammed, Shafiu , Moka, Nagabhishek , Mokdad, Ali H. , Molokhia, Mariam , Monasta, Lorenzo , Moosavi, Mohammad Amin , Moradi, Yousef , Moraga, Paula , Morgado-da-Costa, Joana, Mubarik, Sumaira , Mwanri, Lillian , Nagarajan, Ahamarshan Jayaraman , Nagata, Chie , Naimzada, Mukhammad David , Nangia, Vinay, Naqvi, Atta Abbas , Swamy, Sreenivas Narasimha, Negoi, Ionuţ , Negru, Șerban , Kandel, Sandhya Neupane , Nguyen, Cuong Tat , Niazi, Robina Khan, Nnaji, Chukwudi A , Noor, Nurulamin M , Nzoputam, Chimezie Igwegbe , Oancea, Bogdan , Ogbo, Felix Akpojene , Olagunju, Andrew T , Olakunde, Babayemi O. , Omar, Emad, Bali, Ahmed Omar , Omonisi, Abidemi , Ong, Sokking, Onwujekwe, Obinna , Ortega-Altamirano, Doris V , Otstavnov, Stanislav S , Mahesh, P A , Pakshir, Keyvan , Pană, Adrian , Panagiotakos, Demosthenes B. , Panda‐Jonas, Songhomitra, Park, Eun‐Cheol , Park, Eun‐Kee , Kan, Fatemeh Pashazadeh , Patel, Harsh K. , Patel, Jenil , Pati, Siddhartha , Paudel, Uttam , Pereira, David M. , Pereira, Renato B. , Perianayagam, Arokiasamy , Pillay, Julian David , Pirouzpanah, Saeed , Podder, Indrashis , Postma, Maarten J. , Prashant, Akila , Preoțescu, Liliana , Rabiee, Navid , Radfar, Amir , Radhakrishnan, Raghu , Radhakrishnan, Venkatraman , Rahim, Fakher , Rahimzadeh, Shadi , Rahman, Mosiur , Rahman, Muhammad Aziz , Rajai, Nazanin , Rajesh, Aashish , Ram, Pradhum , Ramezanzadeh, Kiana, Ranabhat, Kamal , Rao, Chythra R , Rao, Sowmya J, Rawassizadeh, Reza , Razeghinia, Mohammad Sadegh , Rezapour, Aziz, Buendía, Jefferson Antonio , Rohloff, Peter , Rwegerera, Godfrey Mutashambara , Manjula, S, Saddik, Basema , Saeed, Umar , Sahoo, Harihar , Salehi, Sana , Salem, Marwa Rashad , Samaei, Mehrnoosh, Samy, Abdallah M , Sanabria, Juan , Sankararaman, Senthilkumar , Santric-Milicevic, Milena M , Sardiwalla, Yaeesh , Sarveazad, Arash , Sathian, Brijesh , Sawhney, Monika, Šekerija, Mario , Seylani, Allen, Shafaat, Omid , Shaikh, Masood Ali , Shannawaz, Mohammed , Sheikhbahaei, Sara , Shetty, Adithi , Shetty, Jeevan K. , Shetty, Pavanchand H, Shirkoohi, Reza , Shivarov, Velizar , Malleshappa, Sudeep K Siddappa , Silva, Diego Augusto Santos , Sintayehu, Yitagesu , Skryabin, Valentin Yurievich , Soeberg, Matthew, Sofi‐Mahmudi, Ahmad , Steiropoulos, Paschalis , Straif, Kurt, Subedi, Ranjeeta , Sultana, Saima , Szerencsés, Viktória , Tabuchi, Takahiro , Tadbiri, Hooman , Takahashi, Ken , Tan, Ker‐Kan , Tat, Vivian Y, Tedla, Bemnet , Tefera, Yonas Getaye , Temsah, Mohamad‐Hani , Tesfay, Fisaha Haile , Tessema, Gizachew Assefa , Thavamani, Aravind , Chandrasekar, Viveksandeep Thoguluva , Touvier, Mathilde , Tovani‐Palone, Marcos Roberto , Traini, Eugenio , Tran, Mai Thi Ngoc , Tripathy, Jaya Prasad , Tusa, Biruk Shalmeno , Ullah, Irfan , Ullah, Saif , Umapathi, Krishna Kishore , Vaezi, Maryam, Tahbaz, Sahel Valadan , Velazquez, Diana Zuleika , Violante, Francesco Saverio , Volovici, Victor , Vu, Giang Thu , Waheed, Yasir , Ward, Paul , Wen, Yi Feng , Westerman, Ronny, Yadav, Lalit , Jabbari, Seyed Hossein Yahyazadeh, Yang, Lin , Yazie, Taklo Simeneh , Yeshaw, Yigizie , Younis, Mustafa Z , Yousefi, Zabihollah , Yunusa, Ismaeel , Zadnik, Vesna , Zare, Fariba , Застрожин, Михаил Сергеевич , Zastrozhina, Anasthasia, Zhang, Jianrong , Zhong, Chenwen, Zhu, Cong , Zimmermann, Ivan Ricardo , Fitzmaurice, Christina , Murray, Christopher J L , Force, Lisa M , Ong, Sok King , Eftekhari, Aziz , Guimarães, André Luiz Sena , Kumar, Vivek , Lami, Faris , Liu, Xuefeng , Baig, Atif Amin , Thoguluva Chandrasekar, Viveksandeep, Kumar, Vivek , Cao, Yin , Brenner, Hermann , Farzadfar, Farshad , Islam, Sheikh Mohammed Shariful , Rahman, Muhammad Aziz , Guha, Avirup , Ebrahimi, Hedyeh , Volovici, Victor , Bhagavathula, Akshaya Srikanth , Jakovljević, Mihajlo , Elhadi, Muhammed , Abdoli, Amir , Adnani, Qorinah Estiningtyas Sakilah , Afzal, Muhammad Sohail, Ahinkorah, Bright Opoku , Ahmad, Sajjad , Ahmadi, Ali , Ahmadi, Sepideh , Akalu, Gizachew Taddesse , Al‐Aly, Ziyad , Ali, Saqib , Aljunid, Syed Mohamed , Almasi‐Hashiani, Amir , Anbesu, Etsay Woldu , Ancuceanu, Robert , Ansari‐Moghaddam, Alireza , Arab-Zozani, Morteza , Asemi, Zatollah , Aujayeb, Avinash , Azzam, Ahmed Y , Banach, Maciej , Barra, Fabio , Behzadifar, Masoud , Bezabhe, Woldesellassie M Mequanint , Bhardwaj, Pankaj , Bhattacharyya, Krittika , Biondi, Antonio , Bjørge, Tone , Bleyer, Archie , Blyuss, Oleg B. , Chaturvedi, Pankaj, Christopher, Devasahayam Jesudas , Chung, Michael T. , Cortesi, Paolo Angelo , Belachew, Amare , Dahlawi, Saad M A , Dai, Xiaochen , Darwesh, Aso Mohammad , Neves, José das , Demis, Asmamaw , Denova‐Gutiérrez, Edgar , Dhimal, Meghnath , Dianatinasab, Mostafa , Do, Huyen Phuc , Doaei, Saeid , Figueiredo, Francisco Winter dos Santos , El-Jaafary, Shaimaa I , Eskandarieh, Sharareh , Faraon, Emerito Jose A , Ferrero, Simone , Filip, Irina , Foroutan, Masoud , Gaál, Péter , Gadanya, Muktar A , Gallus, Silvano , Gomez, Ricardo Santiago , Grosso, Giuseppe , Gupta, Veer Bala , Haj‐Mirzaian, Arvin , Halwani, Rabih , Hamadeh, Randah R , Hamidi, Samer , Haro, Josep María , Hassanipour, Soheil , Hay, Roderick J. , Hayat, Khezar , Heidari, Mohammad , Holla, Ramesh , Hossain, Md Mahbub , Hostiuc, Sorin , Iavicoli, Ivo , Ilesanmi, Olayinka Stephen , Ilić, Milena , Islam, Rakibul M. , Jazayeri, Seyed Behzad , Kabir, Ali , Kahrizi, Danial , Kaliyadan, Feroze , Karch, André , Katikireddi, Srinivasa Vittal , Kauppila, Joonas H. , Kavetskyy, Taras , Kebede, Sewnet Adem , Khan, Gulfaraz , Khang, Young-Ho, Khayamzadeh, Maryam , Kim, Gyu Ri , Kim, Yun Jin , Kissimova‐Skarbek, Katarzyna , Koyanagi, Ai , Kumar, Narinder , Kumar, Nithin , Vecchia, Carlo La , Landires, Iván , Lauriola, Paolo , Lee, Sang Hyuck , Lee, Shaun Wen Huey , Lee, Wei‐Chen , Li, Jiarui , Mansournia, Mohammad Alì , Mathur, Prashant , McKee, Martin , Menezes, Ritesh G. , Meštrović, Tomislav , Mirzaei, Hamed , Moni, Mohammad Ali , Morrison, Shane D. , Mosapour, Abbas , Nagaraju, Shankar Prasad , Ndejjo, Rawlance , Nduaguba, Sabina O. , Nguyen, Huong Lan Thi , Núñez-Samudio, Virginia , Оchir, Chimedsuren , Odukoya, Oluwakemi Ololade , Ong, Sokking, Orru, Hans , Otstavnov, Nikita , Owolabi, Mayowa , Padubidri, Jagadish Rao , Pardhan, Shahina , Pattanshetty, Sanjay M. , Pishgar, Farhad , Pourjafar, Hadi , Rabiee, Mohammad , Rafiee, Ata , Rahmani, Amir Masoud , Rakovac, Ivo , Ranasinghe, Priyanga Diloshini , Renzaho, André M. N. , Rezaei, Negar , Rezaei, Nima , Roberts, Thomas J. , Romoli, Michele , Ronfani, Luca , Roshandel, Gholamreza , Sabour, Siamak , Sahebkar, Amirhossein , Salimzadeh, Hamideh , Şaylan, Mete , Schneider, Ione Jayce Ceola , Shaghaghi, Zahra , Shamsoddin, Erfan , Sharma, Rajesh , Sheikh, Aziz , Shibuya, Kenji , Shivakumar, K. M. , Siabani, Soraya , Singh, Jasvinder A. , Skryabina, Anna Aleksandrovna , Sotoudeh, Houman , Sufiyan, Mu’awiyyah Babale , Sultan, Iyad Yasin , Sur, Daniel Genel , Szócska, Miklós , Tabarés‐Seisdedos, Rafael , Taherkhani, Amir , Talaat, Iman Mamdouh , Tehrani‐Banihashemi, Arash , Thapar, Rekha , Thomas, Nihal , Tohidinik, Hamid Reza , Tran, Bach Xuan , Tran, Khanh Bao , Unnikrishnan, Bhaskaran , Upadhyay, Era , Vacante, Marco , Vaezi, Maryam, Veroux, Massimiliano , Vlassov, Vasily , Vo, Bay, Wamai, Richard G. , Winkler, Andrea Sylvia , Yaya, Sanni , Yonemoto, Naohiro , Yu, Chuanhua , Yüce, Deniz , Zhou, Linghui , Ziapour, Arash , Olagunju, Andrew T , Shivakumar, KM , Baig, Atif Amin , Alahdab, Fares , Asghari-Jafarabadi, Mohammad , Rahim, Fakher

Mayo Clinic

JAMA Oncology | December 30, 2021 | Volume: 8 | Issue: 3 | Pages: 420

10.1001/jamaoncol.2021.6987 | PMID 34967848 Get It

Genetic variants associated with circulating C‐reactive protein levels and colorectal cancer survival: Sex‐specific and lifestyle factors specific associations
Huang, Yu‐Han , Hua, Xinwei , Labadie, Julia , Harrison, Tabitha A. , Dai, James Y. , Lindström, Sara , Berndt, Sonja I. , Buchanan, Daniel D. , Casey, Graham , Gallinger, Steven , Gunter, Marc J. , Hoffmeister, Michael , Diergaarde, Brenda , Slattery, Martha L. , Brenner, Hermann , Chang‐Claude, Jenny , Joshi, Amit D. , Pai, Rish K. , Peters, Ulrike , Buchanan, Daniel D , Hoffmeister, Michael , Slattery, Martha L , Newcomb, Polly A. , Gunter, Marc J , Harrison, Tabitha A , Brenner, Hermann , Dai, James Y , Diergaarde, Brenda , Lin, Yi , Campbell, Peter T. , Jenkins, Mark A. , Sakoda, Lori C. , Schoen, Robert E. , White, Emily E. , Giles, Graham G. , Ma, Wenjie , Chan, Andrew T.

Mayo Clinic

International Journal of Cancer | December 10, 2021 | Volume: 150 | Issue: 9 | Pages: 1447-1454

10.1002/ijc.33897 | PMID 34888857 Get It

AbstractElevated blood levels of C‐reactive protein (CRP) have been linked to colorectal cancer (CRC) survival. We evaluated genetic variants associated with CRP levels and their interactions with sex and lifestyle factors in association with CRC‐specific mortality. Our study included 16 142 CRC cases from the International Survival Analysis in Colorectal Cancer Consortium. We identified 618 common single nucleotide polymorphisms (SNPs) associated with CRP levels from the NHGRI‐EBI GWAS Catalog. Cox proportional hazards regression was used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for associations between SNPs and CRC‐specific mortality adjusting for age, sex, genotyping platform/study and principal components. We investigated their interactions with sex and lifestyle factors using likelihood ratio tests. Of 5472 (33.9%) deaths accrued over up to 10 years of follow‐up, 3547 (64.8%) were due to CRC. No variants were associated with CRC‐specific mortality after multiple comparison correction. We observed strong evidence of interaction between variant rs1933736 at FRK gene and sex in relation to CRC‐specific mortality (corrected Pinteraction = .0004); women had higher CRC‐specific mortality associated with the minor allele (HR = 1.11, 95% CI = 1.04‐1.19) whereas an inverse association was observed for men (HR = 0.88, 95% CI = 0.82‐0.94). There was no evidence of interactions between CRP‐associated SNPs and alcohol, obesity or smoking. Our study observed a significant interaction between sex and a CRP‐associated variant in relation to CRC‐specific mortality. Future replication of this association and functional annotation of the variant are needed.
Salicylic Acid and Risk of Colorectal Cancer: A Two-Sample Mendelian Randomization Study
Nounu, Aayah , Richmond, Rebecca C. , Stewart, Isobel D., Surendran, Praveen , Wareham, Nicholas J. , Butterworth, Adam S. , Weinstein, Stephanie J. , Figueiredo, Jane C. , Lindor, Noralane M. , Casey, Graham , Marchand, Loı̈c Le , Ulrich, Cornelia M. , Li, Christopher, Dujinhoven, Fränzel van, Gsur, Andrea , Moreno, Vı́ctor , Vodička, Pavel , Vodičková, Ludmila, Alwers, Elizabeth , Chang‐Claude, Jenny , Sakoda, Lori C. , Slattery, Martha L. , Schoen, Robert , Gunter, Marc J. , Castellvı́-Bel, Sergi , Kim, Hyeong Rok , Li, Li , Bishop, D. Timothy , Buchanan, Daniel D. , Gruber, Stephen B. , Rennert, Gad , Harrison, Tabitha A. , Woods, Michael O. , Schafmayer, Clemens , Guelpen, Bethany Van , Gallinger, Steven , Berndt, Sonja I. , Lindblom, Annika , Wu, Anna H. , Peters, Ulrike , Scherer, Dominique , Bermejo, Justo Lorenzo , Brenner, Hermann , Hoffmeister, Michael , Relton, Caroline L. , Drew, David A. , Figueiredo, Jane C , Marchand, Loïc Le , Ulrich, Cornelia M , Gsur, Andrea , Moreno, Victor , Sakoda, Lori C , Castellví-Bel, Sergi , Buchanan, Daniel D , Lorenzo-Bermejo, Justo , Hoffmeister, Michael , Rennert, Gad , Gunter, Marc J , Drew, David A , Harrison, Tabitha A , Van Guelpen, Bethany , Brenner, Hermann , Bishop, D Timothy , Vodicka, Pavel , Lindblom, Annika , Albanes, Demetrius , Baron, John A. , Hopper, John L. , Newcomb, Polly A. , Platz, Elizabeth A. , Campbell, Peter T. , Amitay, Efrat L. , Schoen, Robert, Kweon, Sun-Seog , Chan, Andrew T. , Zheng, Wei , Giles, Graham G. , Stadler, Zsofia , Lin, Yi , Keku, Temitope O , Hampel, Heather , Pharoah, Paul D.P. , Wolk, Alicja , White, Emily , Williams, Ann Caroline

Mayo Clinic

Nutrients | November 21, 2021 | Volume: 13 | Issue: 11 | Pages: 4164

10.3390/nu13114164 | PMID 34836419 Get It

Salicylic acid (SA) has observationally been shown to decrease colorectal cancer (CRC) risk. Aspirin (acetylsalicylic acid, that rapidly deacetylates to SA) is an effective primary and secondary chemopreventive agent. Through a Mendelian randomization (MR) approach, we aimed to address whether levels of SA affected CRC risk, stratifying by aspirin use. A two-sample MR analysis was performed using GWAS summary statistics of SA (INTERVAL and EPIC-Norfolk, N = 14,149) and CRC (CCFR, CORECT, GECCO and UK Biobank, 55,168 cases and 65,160 controls). The DACHS study (4410 cases and 3441 controls) was used for replication and stratification of aspirin-use. SNPs proxying SA were selected via three methods: (1) functional SNPs that influence the activity of aspirin-metabolising enzymes; (2) pathway SNPs present in enzymes’ coding regions; and (3) genome-wide significant SNPs. We found no association between functional SNPs and SA levels. The pathway and genome-wide SNPs showed no association between SA and CRC risk (OR: 1.03, 95% CI: 0.84–1.27 and OR: 1.08, 95% CI: 0.86–1.34, respectively). Results remained unchanged upon aspirin use stratification. We found little evidence to suggest that an SD increase in genetically predicted SA protects against CRC risk in the general population and upon stratification by aspirin use.